Effects of amiodarone, amioder, and dronedarone on Trichomonas vaginalis.
Amiodarone
Amioder
Chemotherapy
Dronedarone
Trichomoniasis
Journal
Parasitology research
ISSN: 1432-1955
Titre abrégé: Parasitol Res
Pays: Germany
ID NLM: 8703571
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
15
11
2021
accepted:
26
03
2022
pubmed:
19
4
2022
medline:
18
5
2022
entrez:
18
4
2022
Statut:
ppublish
Résumé
Trichomonas vaginalis is a protozoan that causes human trichomoniasis, the most common non-viral sexually transmitted infection (STI) affecting approximately 278 million people worldwide. The current treatment for trichomoniasis is based on 1-(2-hydroxyethyl)-2-methyl-5-nitroimidazole, known as metronidazole (MTZ). Although effective in clearing the parasite infection, MTZ is related to provoking severe side effects, and it is not recommended during pregnancy. In addition, some strains present resistance to 5'-nitroimidazoles, making urgent the development of alternative drugs for trichomoniasis. Amiodarone, an antiarrhythmic drug, exerts a significant anti-parasite effect, mainly due to its interference with calcium homeostasis and the biosynthesis of sterols. Therefore, we decided to test the effect of amiodarone and two other related compounds (amioder and dronedarone) on T. vaginalis. Our observations show that amiodarone stimulated, rather than inhibited, parasite growth, induced cell aggregation, and glycogen accumulation. Furthermore, the other two compounds displayed anti-parasite activity with IC50 of 3.15 and 11 µM, respectively, and the apoptosis-like process killed the cells. In addition, cells exhibited morphological changes, including an effect on hydrogenosomes structure.
Identifiants
pubmed: 35435511
doi: 10.1007/s00436-022-07521-8
pii: 10.1007/s00436-022-07521-8
doi:
Substances chimiques
Metronidazole
140QMO216E
Dronedarone
JQZ1L091Y2
Amiodarone
N3RQ532IUT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1761-1773Subventions
Organisme : FAPERJ
ID : 26/202.824/2017
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Adesse D, Azzam EM, MeirellesMde N, Urbina JA, Garzoni LR (2011) Amiodarone inhibits Trypanosoma cruzi infection and promotes cardiac cell recovery with gap junction and cytoskeleton reassembly in vitro. Antimicrob Agents Chemother 55:203–210. https://doi.org/10.1128/AAC.01129-10
doi: 10.1128/AAC.01129-10
pubmed: 21078932
Benaim G, Casanova P, Hernandez-Rodriguez V et al (2014) Dronedarone, an amiodarone analog with improved anti-Leishmania mexicana efficacy. Antimicrob Agents Chemother 58:2295–2303. https://doi.org/10.1128/AAC.01240-13
doi: 10.1128/AAC.01240-13
pubmed: 24492373
pmcid: 4023776
Benaim G, Hernandez-Rodriguez V, Mujica-Gonzalez S, Plaza-Rojas L, Silva ML, Parra-Gimenez N, Garcia-Marchan Y, Paniz-Mondolfi A, Uzcanga G (2012) In vitro anti-Trypanosoma cruzi activity of dronedarone, a novel amiodarone derivative with an improved safety profile. Antimicrob Agents Chemother 56:3720–3725. https://doi.org/10.1128/AAC.00207-12
doi: 10.1128/AAC.00207-12
pubmed: 22508311
pmcid: 3393446
Benaim G, Paniz-Mondolfi AE (2012) The emerging role of amiodarone and dronedarone in Chagas disease. Nat Rev Cardiol 9:605–609. https://doi.org/10.1038/nrcardio.2012.108
doi: 10.1038/nrcardio.2012.108
pubmed: 22869282
Benaim G, Paniz-Mondolfi AE, Sordillo EM, Martinez-Sotillo N (2020) Disruption of intracellular calcium homeostasis as a therapeutic target against Trypanosoma cruzi. Front Cell Infect Microbiol 10:46. https://doi.org/10.3389/fcimb.2020.00046
doi: 10.3389/fcimb.2020.00046
pubmed: 32133302
pmcid: 7040492
Benaim G, Paniz-Mondolfi AES, EM. (2021) Rationale for use of amiodarone and its derivatives for treatment of Chagas’ disease and leishmaniasis. Curr Pharmac Design 27:1825–1833
doi: 10.2174/1381612826666200928161403
Benaim G, Sanders JM, Garcia-Marchán Y et al (2006) Amiodarone has intrinsic anti- Trypanosoma cruzi activity and acts synergistically with Posaconazole. J Med Chem 49:892–899. https://doi.org/10.1021/jm050691f
doi: 10.1021/jm050691f
pubmed: 16451055
Benchimol M (2008) The hydrogenosome peripheral vesicle: similarities with the endoplasmic reticulum. Tissue Cell 40:61–74. https://doi.org/10.1016/j.tice.2007.09.006
doi: 10.1016/j.tice.2007.09.006
pubmed: 18031780
Diamond LS (1957) The establishment of various trichomonads of animals and man in axenic cultures. J Parasitol 43:488–490
doi: 10.2307/3274682
Docampo R, Moreno SN (2003) Calcium regulation in protozoan parasites. Curr Opin Microbiol 6:359–364. https://doi.org/10.1016/s1369-5274(03)0009)
doi: 10.1016/s1369-5274(03)0009)
pubmed: 12941405
Edwards DI (1993) Nitroimidazole drugs-action and resistance mechanisms I. Mechanisms of Action. J Antimicrob Chemother 31:9–20. https://doi.org/10.1093/jac/31.1.9
doi: 10.1093/jac/31.1.9
pubmed: 8444678
Hejchman E, Ostrowska K, Maciejewska D, Kossakowski J, Courchesne JE (2012) Synthesis and antifungal activity of derivatives of 2- and 3-benzofurancarboxylic acids. J Pharmacol Exp Ther 343:380–388. https://doi.org/10.1124/jpet.112.196980
doi: 10.1124/jpet.112.196980
pubmed: 22892340
Land KM, Clemens DL, Johnson PJ (2001) Loss of multiple hydrogenosomal proteins associated with organelle metabolism and high-level drug resistance in Trichomonads. Exp Parasitol 97:102–110. https://doi.org/10.1006/expr.2001.4587
doi: 10.1006/expr.2001.4587
pubmed: 11281707
Lewis DA (2010) Trichomoniasis. Medicine 38:291–293. https://doi.org/10.1016/j.mpmed.2010.03.007
doi: 10.1016/j.mpmed.2010.03.007
Löfmark S, Edlund C, Nord CE (2010) Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin Infect Dis 50:S16–S23. https://doi.org/10.1086/647939
doi: 10.1086/647939
pubmed: 20067388
Lossick JG (1990) Treatment of sexually transmitted vaginosis/vaginitis. Clin Infect Dis 6:S665-81. https://doi.org/10.1093/clinids/12.Supplement_6.S665
doi: 10.1093/clinids/12.Supplement_6.S665
Martinez-Sotillo N, Pinto-Martínez A, Hejchman E, Benaim G (2019) Antiproliferative effect of a benzofuran derivate based on the structure of amiodarone on Leishmania donovani affecting mitochondria, acidocalcisomes and intracellular Ca2+ homeostasis. Parasitol Int 70:112–117. https://doi.org/10.1016/j.parint.2019.02.006
doi: 10.1016/j.parint.2019.02.006
pubmed: 30794871
Mielczarek E, Blaszkowska J (2016) Trichomonas vaginalis: pathogenicity and potential role in human reproductive failure. Infection 44:447–458. https://doi.org/10.1007/s15010-015-0860-0
doi: 10.1007/s15010-015-0860-0
pubmed: 26546373
Noël JC, Fayt I, Romero Munoz MR, Simon P, Engohan-Aloghe C (2010) High prevalence of high-risk human papillomavirus infection among women with Trichomonas vaginalis infection on monolayer cytology. Arch Gynecol Obstet 282:503–505. https://doi.org/10.1007/s00404-009-1291-x
doi: 10.1007/s00404-009-1291-x
pubmed: 19940998
Oates JA, Wood AJJ, Mason JW (1987) Amiodarone. N Engl J Med 316:455–466. https://doi.org/10.1056/NEJM198702193160807
doi: 10.1056/NEJM198702193160807
Paulish-Miller TE, Augostini P, Schuyler JA, Smith WL, Mordechai E, Adelson ME, Gygax SE, Secor WE, Hilbert DW (2014) Trichomonas vaginalis metronidazole resistance is associated with single nucleotide polymorphisms in the nitroreductase genes ntr4Tv and ntr6Tv. Antimicrob Agents Chemother 58:2938–2943. https://doi.org/10.1128/AAC.02370-13
doi: 10.1128/AAC.02370-13
pubmed: 24550324
pmcid: 3993245
Petrin D, Delgaty K, Bhatt R, Garber G (1998) Clinical and microbiological aspects of Trichomonas vaginalis. Clin Microbiol Rev 11:300–317. https://doi.org/10.1128/CMR.11.2.300
doi: 10.1128/CMR.11.2.300
pubmed: 9564565
pmcid: 106834
Pinto-Martinez A, Hernández-Rodríguez V, Rodríguez-Durán J, Hejchman E, Benaim G (2018) Anti-Trypanosoma cruzi action of a new benzofuran derivative based on amiodarone structure. Exp Parasitol 189:8–15. https://doi.org/10.1016/j.exppara.2018.04.0107
doi: 10.1016/j.exppara.2018.04.0107
pubmed: 29684665
Rein MF (1990) Clinical manifestations of urogenital trichomoniasis in women. Springer, New York, pp 225–234. https://doi.org/10.1007/978-1-4612-3224-7_11
Rocha DA, de Andrade RI, Urbina JA, de Souza W, Benchimol M (2014) The effect of 3-(biphenyl-4-yl)-3-hydoxyquinuclidine (BPQ-OH) and metronidazole on Trichomonas vaginalis: a comparative study. Parasitol Res 113:2185–2197. https://doi.org/10.1007/s00436-014-3871-3
doi: 10.1007/s00436-014-3871-3
pubmed: 24752367
Rosa Ide A, Rocha DA, de Souza W, Urbina JA, Benchimol M (2011) Ultrastructural alterations induced by Δ(24(25))-sterol methyltransferase inhibitors on Trichomonas vaginalis. FEMS Microbiol Lett 315:72–78. https://doi.org/10.1111/j.1574-6968.2010.02178.x
doi: 10.1111/j.1574-6968.2010.02178.x
pubmed: 21175744
Sass G, Madigan RT, Joubert LM, Bozzi A, Sayed N, Wu JC, Stevens DA (2019) A combination of itraconazole and amiodarone is highly effective against Trypanosoma cruzi infection of human stem cell-derived cardiomyocytes. Am J Trop Med Hyg 101:383–391. https://doi.org/10.4269/ajtmh.19-0023
doi: 10.4269/ajtmh.19-0023
pubmed: 31219005
pmcid: 6685576
Serrano-Martín X, García-Marchan Y, Fernandez A, Rodriguez N, Rojas H, Visbal G, Benaim G (2009a) Amiodarone destabilizes intracellular ca
doi: 10.1128/AAC.01215-08
pubmed: 19164149
pmcid: 2663059
Serrano-Martín X, Payares G, De Lucca M, Martinez JC, Mendoza-León A, Benaim G (2009b) Amiodarone and miltefosine act synergistically against Leishmania mexicana and can induce parasitological cure in a murine model of cutaneous leishmaniasis. Antimicrob Agents Chemother 53:5108–5113. https://doi.org/10.1128/AAC.00505-09
doi: 10.1128/AAC.00505-09
pubmed: 19805563
pmcid: 2786335
Sutcliffe S (2006) Plasma antibodies against Trichomonas vaginalis and subsequent risk of prostate cancer. Cancer Epidemiol Biomark Prev 15:939–945. https://doi.org/10.1158/1055-9965.EPI-05-0781
doi: 10.1158/1055-9965.EPI-05-0781
Thiery JP (1967) Mise en evidence des polysaccharides sur coupes fines en microscopie electronique. J Microsc 6:987–1018
Van Der Pol B, Kwok C, Pierre-Louis B, Rinaldi A, Salata RA, Chen PL, van de Wijgert J, Mmiro F, Mugerwa R, Chipato T, Morrison CS (2008) Trichomonas vaginalis infection and human immunodeficiency virus acquisition in african women. J Infect Dis 197:548–554. https://doi.org/10.1086/526496
doi: 10.1086/526496
Veiga-Santos P, Barrias ES, Santos JF, de Barros Moreira TL, de Carvalho TM, Urbina JA, de Souza W (2012) Effects of amiodarone and posaconazole on the growth and ultrastructure of Trypanosoma cruzi. Int J Antimicrob Agents 40:61–71. https://doi.org/10.1016/j.ijantimicag.2012.03.009
doi: 10.1016/j.ijantimicag.2012.03.009
pubmed: 22591838
World Health Organization (2012) Global incidence and prevalence of selected curable sexually transmitted infections – 2008. WHO Press, Genebra
Wright JM, Webb RI, O’Donoghue P, Upcroft P, Upcroft JA (2010) Hydrogenosomes of laboratory-Induced metronidazole-resistant Trichomonas vaginalis lines are downsized while those from clinically metronidazole-resistant isolates are not. J Eukaryot Microbiol 57:171–176. https://doi.org/10.1111/j.1550-7408.2009.00455.x
doi: 10.1111/j.1550-7408.2009.00455.x
pubmed: 20015182